FBP002

About Fast Biopharma

FasT Biopharma is a private, preclinical-stage biotech developing novel anti-FasL antibodies to inhibit pathological cell death. Its lead programs target high-need areas in ophthalmology (glaucoma, dry AMD) and oncology (colorectal cancer), aiming to preserve vision and enhance anti-tumor immunity. The company leverages a deep understanding of the Fas/FasL biology to engineer antibodies tailored for specific routes of administration and disease settings, positioning it to address significant unmet medical needs across multiple therapeutic areas.

Therapeutic Areas